Pan-European mid-market private equity investor Oakley Capital has acquired a majority stake in medical software provider Horizons Optical via its Oakley Capital Origin Fund I from Madrid-based Sherpa Capital.
Horizons’s CEO, Santiago Soler, will continue to lead the company and retain a significant share in the business.
Oakley’s investment will contribute to international growth plans as well as the company’s R&D and sales & marketing departments.
The acquisition marks Oakley’s sixth deal in Spain, following vLex, Seedtag, Alerce, Grupo Primavera (now Cegid) and idealista, as well as Origin I’s ninth investment, after which the fund will be around 75% invested.
In a statement, Peter Dubens, Co-Founder and Managing Partner at Oakley Capital, said: “Horizons Optical has all the hallmarks of a typical Oakley deal: a disruptive market leader, with strong software IP and led by an exceptional management team.
“We look forward to working with Santiago to help the business realise its full potential, taking advantage of strong market growth drivers as well as leveraging our expertise helping to scale software businesses including Grupo Primavera in Iberia.”
Horizons was founded in Barcelona in 2017 and manufactures spectacle lenses for eye conditions including short, mid and farsightedness as well as astigmatism. The company also provides equipment for opticians with the capability to scan consumers’ faces and measure relevant facial parameters for the manufacturing of lenses and frames, including its recently launched virtual reality headset, Mimesys.
Horizons operates in Europe, the US, the APAC and South America.
